Ultragenyx Resubmits BLA for UX111 Gene Therapy Targeting Sanfilippo Syndrome Type A to FDA on February 02, 2026 Accelerated Approved BLA Blackfoot language gene therapy Mucopolysaccharidosis Type IIIA resubmission Ultragenyx United States Food and Drug Administration UX111 +